The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...

On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.

Stocks in Focus. In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...

Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...

Brand collaborations remain a popular tactic for challenger brands to reach new audiences. Bubble Skincare and Touchland will ...

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...

Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

It appears some investors may be coming round to the thinking of Ken Griffin, the billionaire founder of hedge fund Citadel, who recently warned that the "uncertainty and chaos" created by President ...

BofA analysts, in a note this month, said Nvidia's results will mark the "next important test for AI bulls," adding that the company's per-share profit "could have enough substance even if less sizzle ...

Domino's Pizza -- one of the best performing stocks of the last two decades -- headlines Monday's slate of earnings. Hims & Hers Health -- [whose shares tumbled Friday after Novo Nordisk said a shorta ...